Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + cyclophosphamide + vincristine + methotrexate + rituximab + doxorubicin + dexamethasone
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PV-COMRAD 1 + PV-COMRAD 2 is a combination chemotherapy regimen utilized in the Phase 2 RADICAL trial (NCT05253495) for the treatment of newly diagnosed mature B-cell non-Hodgkin lymphoma (MB-NHL) in children, adolescents, and young adults (CAYA). The regimen integrates **polatuzumab vedotin**, an antibody-drug conjugate (ADC) targeting CD79b, into a reduced-toxicity chemotherapy backbone known as **COMRAD** (Cyclophosphamide, Oncovin/vincristine, Methotrexate, Rituximab, Adriamycin/doxorubicin, and Dexamethasone). The '1' and '2' designations refer to the specific treatment cycles within the protocol. The primary objective of this combination is to maintain high disease control rates while reducing the cumulative dose of anthracyclines (doxorubicin), thereby mitigating long-term cardiotoxicity in the pediatric and young adult population.
- Other names
- PV-COMRAD 1 + PV-COMRAD 2Polatuzumab Vedotin plus COMRAD
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainDHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on polatuzumab vedotin + cyclophosphamide + vincristine + methotrexate + rituximab + doxorubicin + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + cyclophosphamide + vincristine + methotrexate + rituximab + doxorubicin + dexamethasone.